Opinion
Video
Other Investigational Treatment Options for SMA
Author(s):
Panelists discuss how combination therapies targeting different aspects of spinal muscular atrophy (SMA), such as myostatin inhibitors (targeting muscle) alongside SMN protein-enhancing treatments, hold promise for addressing fatigue and improving muscle function in older patients.
Clinical Brief: Combination Therapies and Future Directions for SMA
Main Discussion Topics
- Potential benefits of combining treatments with different mechanisms of action
- Myostatin inhibition as a promising complementary therapy
- Chloride channel modulation for neuromuscular function enhancement
- Addressing fatigue and endurance limitations in patients with SMA
Key Points for Physicians
- Combining therapies targeting different aspects of SMA pathophysiology (SMN protein, muscle function) may provide additive benefits.
- Intravenous and subcutaneous myostatin inhibitors show promise in clinical trials when combined with SMN2 modulators.
- Chloride channel inhibitors being studied across multiple neuromuscular conditions could benefit patients with SMA.
- Fatigue management remains a critical unmet need for older patients with SMA.
Notable Insights
The panel expressed particular enthusiasm for combination approaches that address the genetic defect and downstream effects on muscle, potentially offering greater functional benefits than monotherapy.
Clinical Significance
The next phase of SMA treatment will likely involve rational combinations of therapies targeting different pathophysiological mechanisms to maximize functional outcomes and address persistent symptoms such as fatigue and reduced endurance.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
